National Cholesterol Education Program

Adult Treatment Panel III (ATP III) Guidelines Slide Set

1 | 2 | 3 4 | 5 | 6

Return to Menu

SLIDE 1: ATP III Guidelines
Population Groups

Return to Top

SLIDE 2: Special Considerations for Different Population Groups
Younger Adults

• Men 20-35 years; women 20-45 years
• Coronary atherosclerosis accelerated by CHD risk factors
• Routine cholesterol screening recommended starting at age 20
• Hypercholesterolemic patients may need LDL-lowering drugs

Return to Top

SLIDE 3: Special Considerations for Different Population Groups (continued)
Older Adults

• Men 65 years and women 75 years
• High LDL and low HDL still predict CHD
• Benefits of LDL-lowering therapy extend to older adults
• Clinical judgment required for appropriate use of LDL-lowering drugs

Return to Top

SLIDE 4: Special Considerations for Different Population Groups (continued)
Women (Ages 45-75 years)

• CHD in women delayed by 10-15 years (compared to men)
• Most CHD in women occurs after age 65
• For secondary prevention in post-menopausal women
  • Benefits of hormone replacement therapy doubtful
  • Benefits of statin therapy documented in clinical trials

Return to Top

SLIDE 5: Special Considerations for Different Population Groups (continued)
Middle-Aged Men (35-65 years)

• CHD risk in men > women
• High prevalence of CHD risk factors
• Men prone to abdominal obesity and metabolic syndrome
• CHD incidence high in middle-aged men
• Strong clinical trial evidence for benefit of LDL-lowering therapy

Return to Top

SLIDE 6: Special Considerations for Different Population Groups (continued)
Racial and Ethnic Groups

• Absolute risk for CHD may vary in different racial and ethnic groups
  Relative risk from risk factors is similar for all population groups
• ATP III guidelines apply to:
  • African Americans
  • Hispanics
  • Native Americans
  • Asian and Pacific Islanders
  • South Asians

Return to Top